Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.40)
# 377
Out of 4,711 analysts
204
Total ratings
42.25%
Success rate
31.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kristen Kluska
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
AQST Aquestive Therapeutics | Initiates: Overweight | $17 | $3.65 | +365.75% | 1 | Dec 17, 2024 | |
ESPR Esperion Therapeutics | Initiates: Overweight | $8 | $2.19 | +265.30% | 1 | Dec 17, 2024 | |
QURE uniQure | Maintains: Overweight | $28 → $58 | $16.98 | +241.58% | 9 | Dec 10, 2024 | |
RIGL Rigel Pharmaceuticals | Maintains: Neutral | $15 → $25 | $17.09 | +46.28% | 6 | Dec 10, 2024 | |
CDXS Codexis | Reiterates: Overweight | $11 | $5.28 | +108.33% | 6 | Nov 22, 2024 | |
TSHA Taysha Gene Therapies | Reiterates: Overweight | $7 | $1.85 | +278.38% | 15 | Nov 14, 2024 | |
CAPR Capricor Therapeutics | Maintains: Overweight | $25 → $30 | $13.07 | +129.53% | 4 | Nov 14, 2024 | |
FOLD Amicus Therapeutics | Maintains: Overweight | $20 → $21 | $9.80 | +114.29% | 6 | Nov 7, 2024 | |
SRPT Sarepta Therapeutics | Upgrades: Overweight | $152 → $167 | $118.97 | +40.37% | 13 | Nov 7, 2024 | |
RARE Ultragenyx Pharmaceutical | Reiterates: Overweight | $116 | $44.22 | +162.32% | 16 | Nov 6, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $5.70 | +215.79% | 8 | Oct 29, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $85 | $64.50 | +31.78% | 7 | Oct 15, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $3.35 | +108.96% | 9 | Oct 1, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $2.70 | +418.52% | 8 | Sep 20, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $45.18 | +48.30% | 5 | Sep 20, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $64 | $46.24 | +38.41% | 16 | Sep 20, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $4.64 | +180.17% | 7 | Sep 20, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $29 | $7.94 | +265.24% | 12 | Sep 20, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $25.14 | +166.51% | 13 | Sep 20, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $17.40 | +14.94% | 8 | Sep 20, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.35 | - | 3 | Sep 12, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $0.61 | +717.93% | 3 | May 31, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.29 | +1,527.91% | 3 | Apr 30, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $0.56 | +975.27% | 3 | Feb 5, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $1.44 | +1,288.89% | 2 | Aug 30, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $3.10 | +641.94% | 2 | Aug 29, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $0.17 | +10,627.06% | 1 | Aug 24, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $41 | $0.95 | +4,215.79% | 2 | Aug 10, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $4.70 | +8,410.64% | 1 | Mar 17, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $2.48 | +3,327.42% | 3 | Oct 7, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $0.49 | +14,185.71% | 1 | Feb 28, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $1.68 | +2,578.57% | 1 | May 26, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $0.77 | +1,320.64% | 3 | May 7, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $3.80 | +1,478.95% | 2 | Mar 19, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.35 | +6,566.67% | 1 | Dec 1, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $3.05 | +82,522.95% | 2 | Jan 30, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $160 | $0.62 | +25,706.45% | 1 | Jan 9, 2020 |
Aquestive Therapeutics
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $3.65
Upside: +365.75%
Esperion Therapeutics
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $2.19
Upside: +265.30%
uniQure
Dec 10, 2024
Maintains: Overweight
Price Target: $28 → $58
Current: $16.98
Upside: +241.58%
Rigel Pharmaceuticals
Dec 10, 2024
Maintains: Neutral
Price Target: $15 → $25
Current: $17.09
Upside: +46.28%
Codexis
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $5.28
Upside: +108.33%
Taysha Gene Therapies
Nov 14, 2024
Reiterates: Overweight
Price Target: $7
Current: $1.85
Upside: +278.38%
Capricor Therapeutics
Nov 14, 2024
Maintains: Overweight
Price Target: $25 → $30
Current: $13.07
Upside: +129.53%
Amicus Therapeutics
Nov 7, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $9.80
Upside: +114.29%
Sarepta Therapeutics
Nov 7, 2024
Upgrades: Overweight
Price Target: $152 → $167
Current: $118.97
Upside: +40.37%
Ultragenyx Pharmaceutical
Nov 6, 2024
Reiterates: Overweight
Price Target: $116
Current: $44.22
Upside: +162.32%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $5.70
Upside: +215.79%
Oct 15, 2024
Reiterates: Overweight
Price Target: $85
Current: $64.50
Upside: +31.78%
Oct 1, 2024
Reiterates: Overweight
Price Target: $7
Current: $3.35
Upside: +108.96%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $2.70
Upside: +418.52%
Sep 20, 2024
Reiterates: Overweight
Price Target: $67
Current: $45.18
Upside: +48.30%
Sep 20, 2024
Reiterates: Overweight
Price Target: $64
Current: $46.24
Upside: +38.41%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $4.64
Upside: +180.17%
Sep 20, 2024
Reiterates: Overweight
Price Target: $29
Current: $7.94
Upside: +265.24%
Sep 20, 2024
Reiterates: Overweight
Price Target: $67
Current: $25.14
Upside: +166.51%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $17.40
Upside: +14.94%
Sep 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $4.35
Upside: -
May 31, 2024
Reiterates: Overweight
Price Target: $5
Current: $0.61
Upside: +717.93%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.29
Upside: +1,527.91%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $0.56
Upside: +975.27%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $1.44
Upside: +1,288.89%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $3.10
Upside: +641.94%
Aug 24, 2023
Reiterates: Overweight
Price Target: $18
Current: $0.17
Upside: +10,627.06%
Aug 10, 2023
Maintains: Overweight
Price Target: $44 → $41
Current: $0.95
Upside: +4,215.79%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $4.70
Upside: +8,410.64%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $2.48
Upside: +3,327.42%
Feb 28, 2022
Initiates: Overweight
Price Target: $70
Current: $0.49
Upside: +14,185.71%
May 26, 2021
Initiates: Overweight
Price Target: $45
Current: $1.68
Upside: +2,578.57%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $0.77
Upside: +1,320.64%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $3.80
Upside: +1,478.95%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $1.35
Upside: +6,566.67%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $3.05
Upside: +82,522.95%
Jan 9, 2020
Initiates: Overweight
Price Target: $160
Current: $0.62
Upside: +25,706.45%